Currently, there are ongoing trials targeting molecular networks, such as STAT3/5 or menin in acute myeloid leukemia (AML), estrogen receptor in ER+/HER2- breast cancer and MDM2 as part of the p53-MDM2 interaction in various cancer types (11). This evidence concerns the gene ESR1 and breast carcinoma.